Summary
Lisinopril has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Hypertension would be drug repurposing rather than first-in-human development. This does not mean it is approved for Hypertension. ClinicalTrials.gov lists 8 registered trials linking Lisinopril to Hypertension: 8 have completed. The most advanced is Phase 4 (NCT00741585). It plans or enrolled 21983 participants. Registration activity spans 2005 to 2015. The literature layer holds 14 publications for this pair: 4 Cochrane reviews, 4 meta-analyses, 1 randomised controlled trial publication and 5 clinical trial publications. Publication years run from 2009 to 2026. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Essential Hypertension ranks 376 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Not well-characterized as population baseline; routinely framed as irreversible in clinical culture despite contrary trial evidence.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 79.5 (trials 29.5, literature 30.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 0 recruiting, 0 active / not yet recruiting, 8 completed, 0 other |
| Linked publications | 14 (5 clinical trial publications, 4 Cochrane reviews, 4 meta-analyses, 1 randomised controlled trial publication) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT00741585 | Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment 2008 | completed | Phase 4 | 21,983 |
| NCT02184858 | Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension 2014 | completed | Phase 4 | 13 |
| NCT00624065 | Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure 2008 | completed | Phase 3 | 348 |
| NCT00219167 | A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure 2005 | completed | Phase 3 | 355 |
| NCT02603809 | Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension 2015 | completed | Phase 2 | 1,659 |
| NCT00537043 | A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure 2007 | completed | Phase 1 | 24 |
| NCT02412761 | Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension 2013 | completed | Not applicable | 42 |
| NCT02336607 | The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients. 2005 | completed | Not applicable | 529 |
Published literature
- Clinical trial publication Peripheral endothelial and coronary microvascular responses to lipophilic versus hydrophilic ACE inhibitors in newly diagnosed hypertensionYilmaz Y, Celik FB, Atici A et al. · Journal of hypertension · 2026 · PMID 42304654
- Clinical trial publication Individual participant-level analysis of four randomized clinical trials examined therapeutic effects of blood pressure lowering on hierarchical kidney outcome using win statisticsLiu Y, Lyu Y, Liu Y et al. · Kidney international · 2026 · PMID 41903707
- Clinical trial publication Effects of different antihypertensive drug classes on central and ambulatory blood pressure in resistant hypertension: A randomized clinical trialYugar-Toledo JC, Minari TP, de Mello PG et al. · British journal of clinical pharmacology · 2026 · PMID 40859651
- Cochrane review Postpartum management of the hypertensive disorders of pregnancy: a systematic review and meta-analysisTol ID, Khalil A, Cairns AE et al. · American journal of obstetrics and gynecology · 2026 · PMID 41421750
- Meta-analysis Efficacy of pharmacological agents for management of post-partum hypertension: A systematic review and network meta-analysisSingh A, Singh MP, Thakur P et al. · Journal of human hypertension · 2026 · PMID 41663753
- Clinical trial publication Utility of a Systolic Blood Pressure Polygenic Risk Score With Chlorthalidone ResponseArmstrong ND, Srinivasasainagendra V, Patki A et al. · JAMA cardiology · 2024 · PMID 39441603
- Clinical trial publication Prevention of Heart Failure in Hypertension-the Role of Coronary Heart Disease Events Treated With Versus Without Revascularization: The ALLHAT StudyChen V, Davis BR, Kapadia SR et al. · The American journal of cardiology · 2024 · PMID 39243877
- Meta-analysis Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysisHu Y, Liang L, Liu S et al. · Journal of clinical hypertension (Greenwich, Conn.) · 2023 · PMID 37417783
- Randomized controlled trial Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical TrialSundström J, Lind L, Nowrouzi S et al. · JAMA · 2023 · PMID 37039792
- Meta-analysis Pharmacological Treatment of Arterial Hypertension in Children and Adolescents: A Network Meta-AnalysisBurrello J, Erhardt EM, Saint-Hilary G et al. · Hypertension (Dallas, Tex. : 1979) · 2018 · PMID 29967035
- Cochrane review Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicityBrewster LM, van Montfrans GA, Oehlers GP et al. · Internal and emergency medicine · 2016 · PMID 27026378
- Meta-analysis Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trialsWang JG, Yan P, Jeffers BW · Journal of the American Society of Hypertension : JASH · 2014 · PMID 24685006
- Cochrane review The effectiveness of Hibiscus sabdariffa in the treatment of hypertension: a systematic reviewWahabi HA, Alansary LA, Al-Sabban AH et al. · Phytomedicine : international journal of phytotherapy and phytopharmacology · 2010 · PMID 19801187
- Cochrane review Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trialsZou Z, Xi GL, Yuan HB et al. · Journal of human hypertension · 2009 · PMID 18987649
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Lisinopril approved for Hypertension?
Lisinopril has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Hypertension would be drug repurposing rather than first-in-human development. This does not mean it is approved for Hypertension. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Lisinopril in clinical trials for Hypertension?
ClinicalTrials.gov lists 8 registered trials linking Lisinopril to Hypertension: 8 have completed. The most advanced is Phase 4 (NCT00741585). It plans or enrolled 21983 participants. Registration activity spans 2005 to 2015.
What does the evidence show for Lisinopril in Hypertension?
Lisinopril has both completed registered trials and synthesis-level publications linked to Hypertension. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.